KRAS-mutant advanced NSCLC: efficacy and clinical outcomes from network meta-analysis and real-world evidence
Lung cancer remains the leading cause of cancer-related morbidity and mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases [1]. KRAS mutation is one of the most common driver alterations in NSCLC, especially in...
KRAS-mutant advanced NSCLC: efficacy and clinical outcomes from network meta-analysis and real-world evidence
Lung cancer remains the leading cause of cancer-related morbidity and mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases [1]. KRAS mutation is one of the most common driver alterations in NSCLC, especially in...
Merck Launches Phase 3 KANDLELIT-007 Trial in KRAS G12C NSCLC
Merck & Co. has initiated KANDLELIT-007, a global Phase 3 clinical trial evaluating its investigational oral KRAS G12C inhibitor calderasib (MK-1084) in combination with KEYTRUDA QLEX™, a subcutaneous formulation of pembrolizumab with berahyaluronidase alfa-pmph. The study targets the first-line treatment...
Zoldonrasib Earns FDA Breakthrough Therapy Designation in KRAS G12D+ NSCLC
The FDA has granted breakthrough therapy designation to zoldonrasib (RMC-9805), an investigational RAS(ON) KRAS G12D inhibitor, as a treatment for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring KRAS G12D mutations who have previously received anti–PD-(L)1...
Zoldonrasib Earns FDA Breakthrough Therapy Status in KRAS G12D-Mutant NSCLC
The FDA has granted breakthrough therapy designation (BTD) to zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, in KRAS G12D-mutated, locally advanced or metastatic non–small cell lung cancer (NSCLC) previously treated with anti–PD-1/PD-L1 therapy and platinum-based chemotherapy.1 Zoldonrasib is a potent, orally...
Zoldonrasib Nets Breakthrough Therapy Designation in KRAS G12D–Mutated NSCLC
The FDA has granted breakthrough therapy designation to zoldonrasib (RMC-9805-001) for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non–small cell lung cancer (NSCLC) who have previously received anti–PD-1/PD-L1 therapy and platinum-based chemotherapy.1 Zoldonrasib Receives BTD...